C Rad AB

C Rad AB maintains a strong liquidity position with a current ratio of 2.84, indicating the company can cover its short-term obligations more than two and a half times over. The company's debt-to-equity ratio is 0.01, reflecting a minimal reliance on debt financing and a conservative capital structure. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential liquidity constraints if short-term obligations increase.

In terms of profitability, C Rad AB reported a net income of 16.1 million SEK, with a return on equity (ROE) of 5.53% and a return on assets (ROA) of 3.75%. These figures indicate moderate profitability relative to its equity and asset base. The company's operating income of 14.2 million SEK and gross profit of 49.9 million SEK suggest a healthy margin structure, although the ROE and ROA are below the industry median for advanced medical equipment and technology firms.

C Rad AB's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could expose the company to higher concentration risk, particularly if demand in its primary market fluctuates.

Looking ahead, the company's revenue is expected to grow, supported by a positive outlook in the healthcare equipment and technology sector. Analysts have assigned a mean recommendation of 2.00, indicating a "buy" rating, with one analyst specifically recommending a "buy". The company's free cash flow of 18.4 million SEK and operating cash flow of 16.6 million SEK support its ability to fund operations and potentially invest in growth opportunities.

The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. While the company's dilution risk is currently low, the absence of a detailed dilution potential analysis in the provided data means that future capital-raising activities could introduce dilution pressure. The company's conservative debt structure and strong equity position mitigate some of these risks, but the negative net cash position remains a concern.

Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's financial statements and analyst estimates suggest a stable and growing business, with a focus on maintaining profitability and liquidity.

C Rad AB's operating margin of 12.0% significantly exceeds the 75th percentile of its Advanced Medical Equipment cohort.

The company's net margin of 13.6% ranks above the 75th percentile among 196 peer companies in its sector.

Revenue grew at a 14.1% compound annual growth rate over the four-year period ending in fiscal year 2026.

C Rad AB maintains a conservative debt-to-equity ratio of 0.01, well below the cohort median of 0.06.

The single covering analyst maintains a buy recommendation for C Rad AB stock despite recent financial volatility.

The company faces medium liquidity risk, which could constrain operations given the drastic reduction in free cash flow.

Revenue kr 105.8M, −12,9% YoY; Operating income −73,3% YoY.

• ▍Revenue kr 105.8M, −12,9% YoY
• ▍Operating income −73,3% YoY
• ▍Net income −88,5% YoY
• ▍Net margin 1.6%

Revenue kr 112.2M, +12,1% YoY; Operating income kr 21.2M.

• ▍Revenue kr 112.2M, +12,1% YoY
• ▍Operating income kr 21.2M
• ▍Net margin 11.5%

Revenue kr 105.2M, −18,7% YoY; Operating income −53,6% YoY.

• ▍Revenue kr 105.2M, −18,7% YoY
• ▍Operating income −53,6% YoY
• ▍Net income −62,3% YoY
• ▍Free cash flow −49,2% YoY
• ▍Net margin 3.8%

Revenue kr 118.8M, +0,7% YoY; Operating income −29,6% YoY.

• ▍Revenue kr 118.8M, +0,7% YoY
• ▍Operating income −29,6% YoY
• ▍Net income −150,3% YoY
• ▍Free cash flow −129,3% YoY
• ▍Net margin -6.8%

Revenue kr 121.5M; Operating income kr 20.4M.

• ▍Revenue kr 121.5M
• ▍Operating income kr 20.4M
• ▍Net margin 11.9%

Revenue kr 100.1M.

• ▍Revenue kr 100.1M

Revenue kr 129.4M; Operating income kr 18.1M.

• ▍Revenue kr 129.4M
• ▍Operating income kr 18.1M
• ▍Net margin 8.2%

Revenue kr 118.0M; Operating income kr 14.2M.

• ▍Revenue kr 118.0M
• ▍Operating income kr 14.2M
• ▍Net margin 13.6%

Revenue kr 441.9M, −5,8% YoY; Operating income −35,7% YoY.

• ▍Revenue kr 441.9M, −5,8% YoY
• ▍Operating income −35,7% YoY
• ▍Net income −81,5% YoY
• ▍Free cash flow −100,0% YoY
• ▍Net margin 2.4%

Revenue kr 469.0M, +10,4% YoY; Operating income +58,3% YoY.

• ▍Revenue kr 469.0M, +10,4% YoY
• ▍Operating income +58,3% YoY
• ▍Net income +58,9% YoY
• ▍Free cash flow +117,4% YoY
• ▍Net margin 12.0%

Revenue kr 424.6M, +40,9% YoY; Operating income +103,3% YoY.

• ▍Revenue kr 424.6M, +40,9% YoY
• ▍Operating income +103,3% YoY
• ▍Net income +375,0% YoY
• ▍Free cash flow +329,9% YoY
• ▍Net margin 8.4%

Revenue kr 301.3M, +15,4% YoY; Operating income −39,5% YoY.

• ▍Revenue kr 301.3M, +15,4% YoY
• ▍Operating income −39,5% YoY
• ▍Net income −70,2% YoY
• ▍Free cash flow −78,0% YoY
• ▍Net margin 2.5%